fedratinib: Clinical Trials

12 trials of fedratinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 2 recruiting, 1 active not recruiting, 1 not yet recruiting. 12 Phase 2, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 212Completed 7, Recruiting 2, Active not recruiting 1, Not yet recruiting 1, Terminated 1
Phase 14Completed 2, Active not recruiting 1, Not yet recruiting 1

Follow fedratinib: new trials by email Literature Review of fedratinib trials Research Report on fedratinib

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Revumenib in Patients With Myelofibrosis
Revumenib, Ruxolitinib, FEDRATINIB - Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Phase 1 / Phase 2Not yet recruitingJohn Mascarenhas322026-12-012026-07-29
Fedratinib in Combination With Nivolumab
Fedratinib Oral Capsule [Inrebic], Nivolumab - Primary Myelofibrosis, Secondary Myelofibrosis
Phase 2CompletedInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest302022-06-142026-04-08
Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
Fedratinib Pill - Myeloproliferative Neoplasm, Chronic Neutrophilic Leukemia
Phase 2CompletedH. Lee Moffitt Cancer Center and Research Institute252022-03-012026-06-09
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
BMS-986158, Ruxolitinib, Fedratinib - Myelofibrosis
Phase 1 / Phase 2Active not recruitingBristol-Myers Squibb2162021-03-222026-05-08
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
Cyclophosphamide, JAK Inhibitor, Fludarabine - Primary Myelofibrosis, Secondary Myelofibrosis
Phase 2RecruitingFred Hutchinson Cancer Center202021-02-092026-07-20
A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Fedratinib - Primary Myelofibrosis
Phase 1 / Phase 2CompletedBristol-Myers Squibb312020-10-122026-11-12
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Decitabine, Ruxolitinib, Fedratinib - Acute Myeloid Leukemia, Essential Thrombocythemia
Phase 2RecruitingUniversity of Washington252020-03-242026-09-17
Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly
SAR302503 - Myelofibrosis
Phase 2CompletedBristol-Myers Squibb82012-11-012025-03-05
Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib
SAR302503 - Hematopoietic Neoplasm
Phase 2TerminatedBristol-Myers Squibb972012-04-302026-07-16
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
SAR302503 - Hematopoietic Neoplasm
Phase 2CompletedBristol-Myers Squibb812011-10-012025-03-05
Phase 2 Study of SAR302503 in Patients With Myelofibrosis
SAR302503 - Hematopoietic Neoplasm
Phase 2CompletedBristol-Myers Squibb302011-08-012025-03-05
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
SAR302503 (TG101348) - Myelofibrosis
Phase 1 / Phase 2CompletedBristol-Myers Squibb432008-07-312026-10-06

Conditions studied

Primary Myelofibrosis (8)  ·  Hematologic Neoplasms (3)  ·  Myeloproliferative Disorders (2)  ·  Leukemia, Monocytic, Acute (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Leukemia, Neutrophilic, Chronic (1)  ·  Myelodysplastic Syndromes (1)  ·  Myelodysplastic-Myeloproliferative Diseases (1)  ·  Polycythemia Vera (1)  ·  Thrombocythemia, Essential (1)

Sponsors

Bristol-Myers Squibb (7)  ·  Fred Hutchinson Cancer Center (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1)  ·  John Mascarenhas (1)  ·  University of Washington (1)

Countries

United States (9)  ·  Germany (4)  ·  France (3)  ·  Italy (3)  ·  Spain (3)  ·  Australia (2)  ·  Canada (2)  ·  Japan (2)  ·  South Korea (2)  ·  United Kingdom (2)  ·  Austria (1)  ·  Belgium (1)  ·  Greece (1)  ·  Israel (1)  ·  Netherlands (1)

Top investigators

Andrew Kuykendall, MD (1)  ·  Anna Halpern (1)  ·  Anthony M Hunter, MD (1)  ·  Ayalew Tefferi, MD (1)  ·  John Mascarenhas, MD (1)  ·  Rachel B. Salit (1)  ·  Salah-Eddin Al-Batran, Prof. Dr. (1)

Results publications

PMID 28602585, PMID 38967662

NIH funding

2023 (1), P01CA108671 (1)